zanubrutinib


( Last Updated : October 21, 2021)
Generic Name:
zanubrutinib
Project Status:
Active
Therapeutic Area:
Mantle cell lymphoma (MCL)
Manufacturer:
BeiGene Canada ULC
Brand Name:
Brukinsa
Project Line:
Reimbursement Review
Project Number:
PC0267-000
Tumour Type:
Lymphoma
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open21-Sep-21
Call for patient/clinician input closed12-Nov-21
Submission received30-Sep-21
Submission accepted15-Oct-21
Review initiated21-Oct-21
Draft CADTH review report(s) provided to sponsor for comment11-Jan-22
Deadline for sponsors comments20-Jan-22
CADTH review report(s) and responses to comments provided to sponsor25-Feb-22
Expert committee meeting (initial)09-Mar-22
Draft recommendation issued to sponsorMarch 21, 2022
To
March 23, 2022
Draft recommendation posted for stakeholder feedback31-Mar-22
End of feedback period14-Apr-22